Literature DB >> 23158174

Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.

Jennifer C Carr1, Erin A Boese, Philip M Spanheimer, Fadi S Dahdaleh, Molly Martin, Daniel Calva, Blanca Schafer, David M Thole, Terry Braun, Thomas M O'Dorisio, M Sue O'Dorisio, James R Howe.   

Abstract

BACKGROUND: Between 10% and 20% of patients with neuroendocrine tumors (NETs) present with metastases of unknown primary site. Because knowledge of the primary site has important implications for treatment, we set out to define gene-expression profiles to differentiate between small-bowel NETs (SBNETs) and pancreatic NETs (PNETs).
METHODS: RNA was extracted from tumor and normal tissues in 11 patients with SBNETs and 15 patients with PNETs, and qPCR was performed for 367 GPCR genes. Differentially expressed genes were identified using the RT2 Profiler. Whole genome expression analysis was performed on 11 SBNETs, 5 PNETS, and corresponding normal tissues. Statistical significance was evaluated by the Student t test and ANOVA.
RESULTS: Whole-genome analysis revealed 173 significantly differentially expressed genes in SBNETs and normal tissues and in 52 in PNETs. GPCR arrays identified 28 genes in SBNETs and 18 in PNETs, with significant expression differences from normal tissues. In all SBNETs, 2 genes were significantly upregulated by more than fivefold: OXTR and GPR113. No PNETs shared this profile, whereas 73% had a greater than fivefold downregulation of ADORA1 and SCTR. These genes also allowed for determination of the primary site in 8 of 10 liver metastases.
CONCLUSION: Differential expression patterns using as few as 2 to 4 GPCR genes successfully discriminated primary sites in small bowel and pancreatic NETs.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23158174      PMCID: PMC3502942          DOI: 10.1016/j.surg.2012.08.040

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  23 in total

1.  Metagenes and molecular pattern discovery using matrix factorization.

Authors:  Jean-Philippe Brunet; Pablo Tamayo; Todd R Golub; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

2.  Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets.

Authors:  G Capurso; S Lattimore; T Crnogorac-Jurcevic; F Panzuto; M Milione; V Bhakta; N Campanini; S M Swift; C Bordi; G Delle Fave; N R Lemoine
Journal:  Endocr Relat Cancer       Date:  2006-06       Impact factor: 5.678

Review 3.  G-protein-coupled receptor-focused drug discovery using a target class platform approach.

Authors:  Ralf Heilker; Michael Wolff; Christofer S Tautermann; Michael Bieler
Journal:  Drug Discov Today       Date:  2009-01-22       Impact factor: 7.851

4.  Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors.

Authors:  Anne Couvelard; Jiangting Hu; Graham Steers; Dermot O'Toole; Alain Sauvanet; Jacques Belghiti; Pierre Bedossa; Kevin Gatter; Philippe Ruszniewski; Francesco Pezzella
Journal:  Gastroenterology       Date:  2006-09-08       Impact factor: 22.682

5.  Identification of unknown primary tumors in patients with neuroendocrine liver metastases.

Authors:  Sam C Wang; Justin R Parekh; Marlene B Zuraek; Alan P Venook; Emily K Bergsland; Robert S Warren; Eric K Nakakura
Journal:  Arch Surg       Date:  2010-03

6.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

7.  Everolimus for advanced pancreatic neuroendocrine tumors.

Authors:  James C Yao; Manisha H Shah; Tetsuhide Ito; Catherine Lombard Bohas; Edward M Wolin; Eric Van Cutsem; Timothy J Hobday; Takuji Okusaka; Jaume Capdevila; Elisabeth G E de Vries; Paola Tomassetti; Marianne E Pavel; Sakina Hoosen; Tomas Haas; Jeremie Lincy; David Lebwohl; Kjell Öberg
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

8.  Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies.

Authors:  Mark Bloomston; Alan Durkin; Ivana Yang; Mumtaz Rojiani; Alexander S Rosemurgy; Steven Enkmann; Timothy J Yeatman; Emmanuel E Zervos
Journal:  Ann Surg Oncol       Date:  2004-04       Impact factor: 5.344

9.  Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.

Authors:  Edoardo Missiaglia; Irene Dalai; Stefano Barbi; Stefania Beghelli; Massimo Falconi; Marco della Peruta; Lorenzo Piemonti; Gabriele Capurso; Alessia Di Florio; Gianfranco delle Fave; Paolo Pederzoli; Carlo M Croce; Aldo Scarpa
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

10.  Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome.

Authors:  William G Dilley; Somasundaram Kalyanaraman; Sulekha Verma; J Perren Cobb; Jason M Laramie; Terry C Lairmore
Journal:  Mol Cancer       Date:  2005-02-03       Impact factor: 27.401

View more
  8 in total

1.  Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jennifer C Carr; Scott K Sherman; Donghong Wang; Fadi S Dahdaleh; Andrew M Bellizzi; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2013-10-10       Impact factor: 5.344

2.  GIPR expression in gastric and duodenal neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; Jennifer C Carr; Donghong Wang; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  J Surg Res       Date:  2014-01-29       Impact factor: 2.192

Review 3.  Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; James R Howe
Journal:  Clin Cancer Res       Date:  2016-10-15       Impact factor: 12.531

Review 4.  G Protein-Coupled Receptor (GPCR) Expression in Native Cells: "Novel" endoGPCRs as Physiologic Regulators and Therapeutic Targets.

Authors:  Paul A Insel; Andrea Wilderman; Alexander C Zambon; Aaron N Snead; Fiona Murray; Nakon Aroonsakool; Daniel S McDonald; Shu Zhou; Thalia McCann; Lingzhi Zhang; Krishna Sriram; Amy M Chinn; Alexander V Michkov; Rebecca M Lynch; Aaron C Overland; Ross Corriden
Journal:  Mol Pharmacol       Date:  2015-03-03       Impact factor: 4.436

5.  Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.

Authors:  Scott K Sherman; Jennifer C Carr; Donghong Wang; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Surgery       Date:  2013-12       Impact factor: 3.982

6.  Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; Jennifer C Carr; Donghong Wang; Andrew M Bellizzi; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Clin Exp Metastasis       Date:  2014-09-21       Impact factor: 5.150

Review 7.  Current Perspective on the Pathogenesis of Small Intestinal Neuroendocrine Tumors: Progress in Biomarkers and Molecular Events.

Authors:  Ying-Xuan Chen; Jing-Yuan Fang
Journal:  Gastrointest Tumors       Date:  2013-09-12

8.  Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases.

Authors:  John F Tierney; Jennifer Poirier; Sitaram Chivukula; Sam G Pappas; Martin Hertl; Erik Schadde; Xavier Keutgen
Journal:  Int J Endocrinol       Date:  2019-03-12       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.